Phase I Clinical Study on the Safety, Pharmacokinetics and Antitumor Activity of SSGJ-612 in Patients With Advanced Solid Tumors
Latest Information Update: 30 Jun 2025
At a glance
- Drugs SSGJ 612 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
Most Recent Events
- 30 Jun 2025 New trial record